<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01865084</url>
  </required_header>
  <id_info>
    <org_study_id>15122</org_study_id>
    <secondary_id>H6D-MC-LVJJ</secondary_id>
    <nct_id>NCT01865084</nct_id>
  </id_info>
  <brief_title>A Study of Tadalafil for Duchenne Muscular Dystrophy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine if tadalafil can slow the decline in walking
      ability of boys who have Duchenne muscular dystrophy (DMD). The study will also assess the
      safety of tadalafil and any side effects that might be associated with it in boys who have
      DMD. Participants will receive study treatment (tadalafil or placebo) for the first 48 weeks
      of the study, and can then continue into an open label extension (OLE) that consists of two
      periods during which all participants will receive tadalafil. In OLE period 1, all
      participants will receive tadalafil for 48 weeks. Participants completing OLE period 1 will
      continue into OLE period 2 and will receive tadalafil for at least another 48 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study is being terminated for lack of efficacy
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Six Minute Walk Distance (6MWD) in Meters</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>6MWD measured the distance in meters a participant was able to walk in 6 minutes. The study used 6MWD procedure modified specifically for use in boys with Duchenne muscular dystrophy (DMD), including standardized verbal encouragement at specific intervals to maintain attention to the test, and use of a &quot;safety chaser&quot; to walk behind the participant during testing (McDonald et al., 2010a). The LS mean (LSM) change from baseline, standard error was derived using mixed model repeated measures (MMRM) methodology with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline 6MWD as a covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the North Star Ambulatory Assessment (NSAA) Global Score</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>The NSAA is a functional scale specifically designed for ambulant boys with DMD that can provide additional information on motor functions important in maintaining normal ambulation and other activities important to everyday life. The NSAA is a 17-item evaluation of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0, 1, or 2, with higher scores reflecting better performance on the assessment, for a total maximum score of 34. This score was transformed to a 0 to 100 scale for the key analysis (referred to as linearized), with higher transformed scores reflecting better performance.The LS mean (LSM) change from baseline standard error was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Timed Function Tests in Seconds</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Timed function tests included time it took to rise from floor, walk 10 meters, ascend 4 stairs, and descend 4 stairs.The lower the time in seconds taken, the better the performance. The LS mean change from baseline, standard error, was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Persistent 10% Worsening in 6MWD</measure>
    <time_frame>Baseline through Week 48</time_frame>
    <description>Time on study until the 6MWD becomes 10% less than the baseline 6MWD and continues at that level or lower until the end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Persistent 10% Worsening in Timed Function Tests (TFT)</measure>
    <time_frame>Baseline through Week 48</time_frame>
    <description>Time on study until the TFT becomes 10% worse than the baseline TFT and continues at that level or lower until the end of study. The time to persistent 10% worsening is the observed time after baseline until the first observed timepoint where their time used for the TFTs is &gt;110% of the baseline time and all the time values observed afterward are also &gt;110% of baseline. If the participant discontinues prior to experiencing persistent worsening, this outcome for the participant is censored at the date of discontinuation of the double-blind period.
Only participants with complete evaluable data were analyzed. Complete evaluable data was defined as having baseline measurement, complete dates at evaluable visits and a post-baseline measurement at each evaluable visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Scores</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>PODCI includes a Global Functioning Scale and 5 core scales:Upper Extremity and Physical Function,Transfer/Basic Mobility, Sports/Physical Functioning, Pain/Comfort,and Happiness.The Global Functioning Scale is the mean of the mean scores from 4 of the 5 core scales (all except the happiness core scale).The following PODCI scores were prespecified in the protocol for analysis: Global Functioning, Upper Extremity and Physical Function,Transfer/Basic Mobility, and Sports/Physical Functioning. The Global Functioning Scale and each of the core scales were standardized so that a score of &quot;0&quot; represents a poor outcome/worse health, while &quot;100&quot; is the best possible outcome/best health (i.e., complete range of each score is 0 to 100, with higher scores representing better functioning). The LS mean (LSM) change from baseline,standard error was derived using MMRM with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline PODC scale as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil</measure>
    <time_frame>Weeks 4, 12, 24 and 36: -1 Hour up to 24 Hours Postdose</time_frame>
    <description>The data reported are population estimate and inter-patient variability.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">331</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo taken orally once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3 mg/kg Tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.6 mg/kg Tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.6 mg/kg tadalafil taken orally once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>0.3 mg/kg Tadalafil</arm_group_label>
    <arm_group_label>0.6 mg/kg Tadalafil</arm_group_label>
    <other_name>LY450190</other_name>
    <other_name>Cialis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Administered orally</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulant males with Duchenne muscular dystrophy (DMD) confirmed by typical clinical
             presentation (onset of clinical signs or symptoms before 6 years of age supported by
             an elevated serum creatinine kinase level, and ongoing difficulty with walking)
             together with either a record of a genetic confirmation of the DMD diagnosis, or a
             record of muscle biopsy showing near-complete dystrophin deficiency (excluding
             revertant fibers)

          -  Receiving systemic corticosteroids for a minimum of 6 months immediately prior to
             screening, with no significant change in total daily dosage or dosing regimen (except
             those adjusting for weight changes) for a minimum of 3 months immediately prior to
             screening and a reasonable expectation that total daily dosage and dosing regimen will
             not change significantly (except for adjustments for weight) for the duration of the
             study

          -  Able to complete the six minute walk distance (6MWD) test with results within 20% of
             each other at a minimum of 2 pre-randomization assessments

          -  Left ventricular ejection fraction (LVEF) ≥50% as determined by echocardiogram

          -  Written informed consent from parents/legal guardian will be obtained prior to any
             study procedure being performed. In addition, the child may be required to give
             documented assent, if capable.

        Exclusion Criteria:

          -  Symptomatic cardiomyopathy or heart failure

          -  Change in prophylactic treatment for heart failure within 3 months prior to start of
             study treatment

          -  Cardiac rhythm disorder

          -  History of participation in gene or cell-based therapy , or antisense oligonucleotide
             or stop codon read-through therapy

          -  Unable to take orally administered tablets

          -  Use of any pharmacologic treatment, other than corticosteroids, that might have an
             effect on muscle strength within 3 months prior to the start of study treatment (for
             example, growth hormone, anabolic steroids including testosterone)

          -  New or changed treatment with herbal or dietary supplements being taken with an
             expectation of an effect on muscle strength or function during 1 month prior to first
             dose of study drug

          -  Surgery that might have an effect on muscle strength or function within 3 months
             before study entry or planned surgery at any time during the study

          -  Evidence of a lower limb injury that may affect performance on the 6MWD

          -  Severe behavioral problems, including severe autism or attention deficit disorders,
             that may interfere with completion of the 6MWD

          -  Any contraindication to tadalafil (use of any form of organic nitrate, either
             regularly and/or intermittently, or known serious hypersensitivity to tadalafil)

          -  History of significant renal insufficiency or clinical evidence of cirrhosis

          -  Have known allergy to any of the excipients in tadalafil tablets, notably lactose

          -  Current Phosphodiesterase Type 5 (PDE5) inhibitor therapy or treatment within the past
             6 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis - Health Systems</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NW Florida Clinical Research Group</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann and Robert Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Healthcare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State University College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children of the King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital Research Foundation</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Caba</city>
        <zip>C1204AAD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 2V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Munich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aichi</city>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagano</city>
        <zip>390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saitama</city>
        <zip>349-0196</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico, Medical Sciences Campus</name>
      <address>
        <city>San Juan</city>
        <zip>000935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <zip>125412</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, Atkinson L, Reha A, Hirawat S, Miller LL. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010 Apr;41(4):500-10. doi: 10.1002/mus.21544.</citation>
    <PMID>19941337</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2013</study_first_submitted>
  <study_first_submitted_qc>May 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2013</study_first_posted>
  <results_first_submitted>September 30, 2016</results_first_submitted>
  <results_first_submitted_qc>January 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 1, 2017</results_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo taken orally once daily.</description>
        </group>
        <group group_id="P2">
          <title>0.3 mg/kg Tadalafil</title>
          <description>0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily.</description>
        </group>
        <group group_id="P3">
          <title>0.6 mg/kg Tadalafil</title>
          <description>0.6 mg/kg tadalafil taken orally once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double Blind Period (DB)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="98">One participant stopped therapy during the DB period but remained in the study for follow-up.</participants>
                <participants group_id="P3" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Parent/Guardian</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label Extension (OLE) Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants who were on Placebo during the double blind period were assigned tadalafil during OLE.</participants>
                <participants group_id="P2" count="150">Participants who were on Placebo during the double blind period were assigned tadalafil during OLE.</participants>
                <participants group_id="P3" count="165">Participants who were on Placebo during the double blind period were assigned tadalafil during OLE.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Parent/Guardian</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who were randomized to study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo taken orally once daily.</description>
        </group>
        <group group_id="B2">
          <title>0.3 mg/kg Tadalafil</title>
          <description>0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily.</description>
        </group>
        <group group_id="B3">
          <title>0.6 mg/kg Tadalafil</title>
          <description>0.6 mg/kg tadalafil taken orally once daily.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="116"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="113"/>
            <count group_id="B4" value="331"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.4" spread="1.76"/>
                    <measurement group_id="B2" value="9.9" spread="2.26"/>
                    <measurement group_id="B3" value="9.5" spread="1.71"/>
                    <measurement group_id="B4" value="9.6" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="262"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Six Minute Walk Distance (6MWD) in Meters</title>
        <description>6MWD measured the distance in meters a participant was able to walk in 6 minutes. The study used 6MWD procedure modified specifically for use in boys with Duchenne muscular dystrophy (DMD), including standardized verbal encouragement at specific intervals to maintain attention to the test, and use of a &quot;safety chaser&quot; to walk behind the participant during testing (McDonald et al., 2010a). The LS mean (LSM) change from baseline, standard error was derived using mixed model repeated measures (MMRM) methodology with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline 6MWD as a covariate.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>All randomized participants who received at least one dose of study drug who had a baseline and at least one post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo taken orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>0.3 mg/kg Tadalafil</title>
            <description>0.3 mg/kg tadalafil taken orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg/kg Tadalafil</title>
            <description>0.6 mg/kg taken tadalafil orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Six Minute Walk Distance (6MWD) in Meters</title>
          <description>6MWD measured the distance in meters a participant was able to walk in 6 minutes. The study used 6MWD procedure modified specifically for use in boys with Duchenne muscular dystrophy (DMD), including standardized verbal encouragement at specific intervals to maintain attention to the test, and use of a &quot;safety chaser&quot; to walk behind the participant during testing (McDonald et al., 2010a). The LS mean (LSM) change from baseline, standard error was derived using mixed model repeated measures (MMRM) methodology with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline 6MWD as a covariate.</description>
          <population>All randomized participants who received at least one dose of study drug who had a baseline and at least one post-baseline measurement.</population>
          <units>Meters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.99" spread="9.316"/>
                    <measurement group_id="O2" value="-64.71" spread="9.809"/>
                    <measurement group_id="O3" value="-59.08" spread="9.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.307</p_value>
            <p_value_desc>The p-value is based on the treatment difference LS Mean changes from baseline between tadalafil and placebo.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.538</p_value>
            <p_value_desc>The p-value is based on the treatment difference LS Mean changes from baseline between tadalafil and placebo.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the North Star Ambulatory Assessment (NSAA) Global Score</title>
        <description>The NSAA is a functional scale specifically designed for ambulant boys with DMD that can provide additional information on motor functions important in maintaining normal ambulation and other activities important to everyday life. The NSAA is a 17-item evaluation of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0, 1, or 2, with higher scores reflecting better performance on the assessment, for a total maximum score of 34. This score was transformed to a 0 to 100 scale for the key analysis (referred to as linearized), with higher transformed scores reflecting better performance.The LS mean (LSM) change from baseline standard error was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>All randomized participants who received at least one dose of study drug who had a baseline and at least one post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo taken orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>0.3 mg/kg Tadalafil</title>
            <description>0.3 mg/kg tadalafil taken orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg/kg Tadalafil</title>
            <description>0.6 mg/kg tadalafil taken orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the North Star Ambulatory Assessment (NSAA) Global Score</title>
          <description>The NSAA is a functional scale specifically designed for ambulant boys with DMD that can provide additional information on motor functions important in maintaining normal ambulation and other activities important to everyday life. The NSAA is a 17-item evaluation of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0, 1, or 2, with higher scores reflecting better performance on the assessment, for a total maximum score of 34. This score was transformed to a 0 to 100 scale for the key analysis (referred to as linearized), with higher transformed scores reflecting better performance.The LS mean (LSM) change from baseline standard error was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.</description>
          <population>All randomized participants who received at least one dose of study drug who had a baseline and at least one post-baseline measurement.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.80" spread="1.104"/>
                    <measurement group_id="O2" value="-9.31" spread="1.181"/>
                    <measurement group_id="O3" value="-8.96" spread="1.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Timed Function Tests in Seconds</title>
        <description>Timed function tests included time it took to rise from floor, walk 10 meters, ascend 4 stairs, and descend 4 stairs.The lower the time in seconds taken, the better the performance. The LS mean change from baseline, standard error, was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>All randomized participants who received at least one dose of study drug who had a baseline and at least one post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo taken orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>0.3 mg/kg Tadalafil</title>
            <description>0.3 mg/kg tadalafil taken orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg/kg Tadalafil</title>
            <description>0.6 mg/kg tadalafil taken orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Timed Function Tests in Seconds</title>
          <description>Timed function tests included time it took to rise from floor, walk 10 meters, ascend 4 stairs, and descend 4 stairs.The lower the time in seconds taken, the better the performance. The LS mean change from baseline, standard error, was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.</description>
          <population>All randomized participants who received at least one dose of study drug who had a baseline and at least one post-baseline measurement.</population>
          <units>Seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rise from the Floor(n=92,75,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="1.120"/>
                    <measurement group_id="O2" value="3.60" spread="1.223"/>
                    <measurement group_id="O3" value="4.81" spread="1.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 Meter Walk/Run(n=105,90,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="0.204"/>
                    <measurement group_id="O2" value="0.95" spread="0.226"/>
                    <measurement group_id="O3" value="1.12" spread="0.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stair Climb (n=116,96,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.96" spread="1.041"/>
                    <measurement group_id="O2" value="4.10" spread="1.154"/>
                    <measurement group_id="O3" value="5.82" spread="1.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stair Descend(n=115,95,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" spread="0.827"/>
                    <measurement group_id="O2" value="2.07" spread="0.915"/>
                    <measurement group_id="O3" value="3.27" spread="0.853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Persistent 10% Worsening in 6MWD</title>
        <description>Time on study until the 6MWD becomes 10% less than the baseline 6MWD and continues at that level or lower until the end of study.</description>
        <time_frame>Baseline through Week 48</time_frame>
        <population>All randomized participants who received at least one dose of study drug who had complete evaluable data. Complete evaluable data was defined as having baseline measurement, complete dates at evaluable visits and a post-baseline measurement at each evaluable visit. Censored participants: placebo=71, 0.3 mg/kg=63, 0.6 mg/kg=61.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo taken orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>0.3 mg/kg Tadalafil</title>
            <description>0.3 mg/kg tadalafil taken orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg/kg Tadalafil</title>
            <description>0.6 mg/kg tadalafil taken orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Persistent 10% Worsening in 6MWD</title>
          <description>Time on study until the 6MWD becomes 10% less than the baseline 6MWD and continues at that level or lower until the end of study.</description>
          <population>All randomized participants who received at least one dose of study drug who had complete evaluable data. Complete evaluable data was defined as having baseline measurement, complete dates at evaluable visits and a post-baseline measurement at each evaluable visit. Censored participants: placebo=71, 0.3 mg/kg=63, 0.6 mg/kg=61.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">These statistics were not estimable due to large number of participants who were censored.</measurement>
                    <measurement group_id="O2" value="NA">These statistics were not estimable due to large number of participants who were censored.</measurement>
                    <measurement group_id="O3" value="NA">These statistics were not estimable due to large number of participants who were censored.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Persistent 10% Worsening in Timed Function Tests (TFT)</title>
        <description>Time on study until the TFT becomes 10% worse than the baseline TFT and continues at that level or lower until the end of study. The time to persistent 10% worsening is the observed time after baseline until the first observed timepoint where their time used for the TFTs is &gt;110% of the baseline time and all the time values observed afterward are also &gt;110% of baseline. If the participant discontinues prior to experiencing persistent worsening, this outcome for the participant is censored at the date of discontinuation of the double-blind period.
Only participants with complete evaluable data were analyzed. Complete evaluable data was defined as having baseline measurement, complete dates at evaluable visits and a post-baseline measurement at each evaluable visit.</description>
        <time_frame>Baseline through Week 48</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug who had complete evaluable data.Censored participants:Rise from Floor;placebo(pl)=40,0.3 mg/kg=39,0.6 mg/kg=43;Stair Climb;pl=55,0.3 mg/kg=45,0.6 mg/kg=52;10 Meter Walk/Run pl=61,0.3 mg/kg=65,0.6 mg/kg=58,Stair Descend;pl=63,0.3 mg/kg=60,0.6 mg/kg=59.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo taken orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>0.3 mg/kg Tadalafil</title>
            <description>0.3 mg/kg tadalafil taken orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg/kg Tadalafil</title>
            <description>0.6 mg/kg tadalafil taken orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Persistent 10% Worsening in Timed Function Tests (TFT)</title>
          <description>Time on study until the TFT becomes 10% worse than the baseline TFT and continues at that level or lower until the end of study. The time to persistent 10% worsening is the observed time after baseline until the first observed timepoint where their time used for the TFTs is &gt;110% of the baseline time and all the time values observed afterward are also &gt;110% of baseline. If the participant discontinues prior to experiencing persistent worsening, this outcome for the participant is censored at the date of discontinuation of the double-blind period.
Only participants with complete evaluable data were analyzed. Complete evaluable data was defined as having baseline measurement, complete dates at evaluable visits and a post-baseline measurement at each evaluable visit.</description>
          <population>All randomized participants who received at least 1 dose of study drug who had complete evaluable data.Censored participants:Rise from Floor;placebo(pl)=40,0.3 mg/kg=39,0.6 mg/kg=43;Stair Climb;pl=55,0.3 mg/kg=45,0.6 mg/kg=52;10 Meter Walk/Run pl=61,0.3 mg/kg=65,0.6 mg/kg=58,Stair Descend;pl=63,0.3 mg/kg=60,0.6 mg/kg=59.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rise from the Floor (n=81,67,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.0" lower_limit="170.0">These statistics were not estimable due to large number of participants who were censored.</measurement>
                    <measurement group_id="O2" value="NA">These statistics were not estimable due to large number of participants who were censored.</measurement>
                    <measurement group_id="O3" value="NA">These statistics were not estimable due to large number of participants who were censored.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stair Climb (n=112,91,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255.0" lower_limit="252.0">These statistics were not estimable due to large number of participants who were censored.</measurement>
                    <measurement group_id="O2" value="259.0" lower_limit="176.0">These statistics were not estimable due to large number of participants who were censored.</measurement>
                    <measurement group_id="O3" value="253.0" lower_limit="185.0">These statistics were not estimable due to large number of participants who were censored.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 Meter Walk/Run (n=98,83,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">These statistics were not estimable due to large number of participants who were censored.</measurement>
                    <measurement group_id="O2" value="NA">These statistics were not estimable due to large number of participants who were censored.</measurement>
                    <measurement group_id="O3" value="NA">These statistics were not estimable due to large number of participants who were censored.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stair Descend (n=110,91,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">These statistics were not estimable due to large number of participants who were censored.</measurement>
                    <measurement group_id="O2" value="NA">These statistics were not estimable due to large number of participants who were censored.</measurement>
                    <measurement group_id="O3" value="NA">These statistics were not estimable due to large number of participants who were censored.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Scores</title>
        <description>PODCI includes a Global Functioning Scale and 5 core scales:Upper Extremity and Physical Function,Transfer/Basic Mobility, Sports/Physical Functioning, Pain/Comfort,and Happiness.The Global Functioning Scale is the mean of the mean scores from 4 of the 5 core scales (all except the happiness core scale).The following PODCI scores were prespecified in the protocol for analysis: Global Functioning, Upper Extremity and Physical Function,Transfer/Basic Mobility, and Sports/Physical Functioning. The Global Functioning Scale and each of the core scales were standardized so that a score of &quot;0&quot; represents a poor outcome/worse health, while &quot;100&quot; is the best possible outcome/best health (i.e., complete range of each score is 0 to 100, with higher scores representing better functioning). The LS mean (LSM) change from baseline,standard error was derived using MMRM with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline PODC scale as covariate.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>All randomized participants who received at least one dose of study drug who had a baseline and at least one post-baseline measurement. The reason the number of participants analyzed is significantly less than the total number of randomized participants is because PODCI was administered only in English.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo taken orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>0.3 mg/kg Tadalafil</title>
            <description>0.3 mg/kg tadalafil taken orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg/kg Tadalafil</title>
            <description>0.6 mg/kg tadalafil taken orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Scores</title>
          <description>PODCI includes a Global Functioning Scale and 5 core scales:Upper Extremity and Physical Function,Transfer/Basic Mobility, Sports/Physical Functioning, Pain/Comfort,and Happiness.The Global Functioning Scale is the mean of the mean scores from 4 of the 5 core scales (all except the happiness core scale).The following PODCI scores were prespecified in the protocol for analysis: Global Functioning, Upper Extremity and Physical Function,Transfer/Basic Mobility, and Sports/Physical Functioning. The Global Functioning Scale and each of the core scales were standardized so that a score of &quot;0&quot; represents a poor outcome/worse health, while &quot;100&quot; is the best possible outcome/best health (i.e., complete range of each score is 0 to 100, with higher scores representing better functioning). The LS mean (LSM) change from baseline,standard error was derived using MMRM with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline PODC scale as covariate.</description>
          <population>All randomized participants who received at least one dose of study drug who had a baseline and at least one post-baseline measurement. The reason the number of participants analyzed is significantly less than the total number of randomized participants is because PODCI was administered only in English.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Global Functioning Scale (n=41,34,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.81" spread="1.770"/>
                    <measurement group_id="O2" value="-7.36" spread="1.929"/>
                    <measurement group_id="O3" value="-7.34" spread="1.888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Extremity &amp; Physical Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.47" spread="1.901"/>
                    <measurement group_id="O2" value="-3.73" spread="2.060"/>
                    <measurement group_id="O3" value="-2.47" spread="2.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transfer/Basic Mobility Core Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.26" spread="3.037"/>
                    <measurement group_id="O2" value="-12.50" spread="3.260"/>
                    <measurement group_id="O3" value="-12.78" spread="3.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sports/Physical Functioning Core Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.47" spread="2.362"/>
                    <measurement group_id="O2" value="-11.98" spread="2.552"/>
                    <measurement group_id="O3" value="-7.88" spread="2.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil</title>
        <description>The data reported are population estimate and inter-patient variability.</description>
        <time_frame>Weeks 4, 12, 24 and 36: -1 Hour up to 24 Hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 mg/kg Tadalafil and 0.6 mg/kg Tadalafil</title>
            <description>0.3 mg/kg tadalafil taken orally once daily.
0.6 mg/kg tadalafil taken orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil</title>
          <description>The data reported are population estimate and inter-patient variability.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>Liter per hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All randomized participants who received at least one dose of study drug for Placebo - DB, 0.3 mg/kg Tadalafil -DB and 0.6 mg/kg Tadalafil - DB arms during the DB period.
All randomized participants who received at least one dose of study drug for 0.3 mg/kg Tadalafil - OLE and 0.6 mg/kg Tadalafil - OLE arms during the OLE period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo - DB</title>
          <description>Placebo taken orally once daily.</description>
        </group>
        <group group_id="E2">
          <title>0.3 mg/kg Tadalafil -DB</title>
          <description>0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily.</description>
        </group>
        <group group_id="E3">
          <title>0.6 mg/kg Tadalafil - DB</title>
          <description>0.6 mg/kg tadalafil taken orally once daily.</description>
        </group>
        <group group_id="E4">
          <title>0.3 mg/kg Tadalafil - OLE</title>
          <description>0.3 mg/kg tadalafil taken orally once daily.</description>
        </group>
        <group group_id="E5">
          <title>0.6 mg/kg Tadalafil - OLE</title>
          <description>0.6 mg/kg tadalafil taken orally once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pneumonia adenoviral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Tendinous contracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Self injurious behaviour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="68" subjects_at_risk="150"/>
                <counts group_id="E5" subjects_affected="84" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="112"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="116"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E3" events="19" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E4" events="13" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="116"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E3" events="25" subjects_affected="17" subjects_at_risk="112"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E5" events="11" subjects_affected="10" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abasia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="102"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="150"/>
                <counts group_id="E5" events="16" subjects_affected="16" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="16" subjects_at_risk="116"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E3" events="24" subjects_affected="18" subjects_at_risk="112"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="116"/>
                <counts group_id="E2" events="21" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="112"/>
                <counts group_id="E4" events="15" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="41" subjects_affected="24" subjects_at_risk="116"/>
                <counts group_id="E2" events="30" subjects_affected="18" subjects_at_risk="102"/>
                <counts group_id="E3" events="41" subjects_affected="22" subjects_at_risk="112"/>
                <counts group_id="E4" events="22" subjects_affected="16" subjects_at_risk="150"/>
                <counts group_id="E5" events="18" subjects_affected="15" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="92" subjects_affected="36" subjects_at_risk="116"/>
                <counts group_id="E2" events="57" subjects_affected="40" subjects_at_risk="102"/>
                <counts group_id="E3" events="68" subjects_affected="43" subjects_at_risk="112"/>
                <counts group_id="E4" events="12" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E5" events="19" subjects_affected="14" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erection increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="112"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Spontaneous penile erection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="102"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="112"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="116"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="112"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The Sponsor concluded that the efficacy results do not provide sufficient justification for continuance of the open-label extension (OLE) period of the study, where all participants were receiving daily treatment with tadalafil.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

